KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Goodwill: 2012-2023

Historic Goodwill for Pacira BioSciences (PCRX) over the last 12 years, with Dec 2023 value amounting to $163.2 million.

  • Pacira BioSciences' Goodwill was N/A to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year change of. This contributed to the annual value of $163.2 million for FY2023, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2023, Pacira BioSciences' Goodwill is $163.2 million, which was down 0.00% from $163.2 million recorded in FY2022.
  • In the past 5 years, Pacira BioSciences' Goodwill registered a high of $163.2 million during FY2022, and its lowest value of $99.5 million during FY2019.
  • For the 3-year period, Pacira BioSciences' Goodwill averaged around $157.2 million, with its median value being $163.2 million (2023).
  • Data for Pacira BioSciences' Goodwill shows a peak YoY soared of 60.46% (in 2019) over the last 5 years.
  • Pacira BioSciences' Goodwill (Yearly) stood at $99.5 million in 2019, then remained steady at $99.5 million in 2020, then skyrocketed by 45.86% to $145.2 million in 2021, then increased by 12.43% to $163.2 million in 2022, then remained steady at $163.2 million in 2023.